Discover how the FDA guarantees generic drugs match brand names through rigorous bioequivalence testing and strict manufacturing standards under the Hatch-Waxman Act.
Learn what the FDA requires from manufacturers to prove bioequivalence for generic drugs. This guide explains the 80-125 rule, ANDA submissions, biowaivers, and special criteria for narrow therapeutic index drugs.
Discover the real timeline for FDA generic drug approvals in 2025 - from the standard 10-month review to fast-tracked options, complex product delays, and how AI is speeding things up. Know what affects approval time and how to plan accordingly.